Allogeneic CD34+-enriched and CD45RA-depleted PBSCs (Fred Hutchinson Cancer Research Center)

N/A

Report date: 2024/01/02 20:03:52

Base Information

Drug NameAllogeneic CD34+-enriched and CD45RA-depleted PBSCs (Fred Hutchinson Cancer Research Center)
Drug Alias NameAllogeneic TN-depleted CD34-preserved PBSCsAllogeneic TND- CD34+ PBSCsDonor-derived TN Cell Depleted CD34-enriched PBSCsNaive T-cell Depleted CD34+ Allogeneic Peripheral Blood Stem Cells
ClassificationCell and gene therapy > Cell therapy > Source of cells > Peripheral blood-derivedCell and gene therapy > Cell therapy > Stem cell therapyCell and gene therapy > Cell therapy > Donor > Allogeneic
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research CenterNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer InstituteFred Hutchinson Cancer Research Center
Inactive CompaniesN/A
Active IndicationsMyeloproliferative DisordersMyelodysplastic SyndromesLeukemia, Myeloid, Acute +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A